- Report
- May 2024
- 128 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 135 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €455EUR$500USD£390GBP
Toviaz is a brand of urological disorder drugs used to treat overactive bladder (OAB). It is a type of antimuscarinic drug, which works by blocking certain nerve signals that cause bladder contractions. Toviaz is used to reduce the number of sudden, strong urges to urinate, as well as the number of times a person needs to urinate during the day and night. It is also used to reduce leakage of urine, which can occur with OAB.
Toviaz is available in both immediate-release and extended-release tablets. The extended-release tablets are designed to provide a steady level of medication throughout the day. Common side effects of Toviaz include dry mouth, constipation, and blurred vision.
The Toviaz market is composed of several companies that manufacture and distribute the drug. These include Pfizer, Inc., Mylan N.V., and Teva Pharmaceutical Industries Ltd. Show Less Read more